Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Gilead Seeks Label Expansion for Epclusa in Japan
September 29, 2021
- Shionogi Out-Licenses Ultra-Long-Acting HIV Drug to ViiV
September 29, 2021
- Shionogi Kicks Off Japan PII/III Trial for Oral COVID-19 Drug
September 29, 2021
- Eisai/Biogen Begin US Rolling Submission for Alzheimer’s Med Lecanemab
September 28, 2021
- Takeda’s Cell Therapy Alofisel Approved in Japan
September 28, 2021
- ASKA Earns Japan Rights to Takeda’s Relugolix Combo Drug
September 28, 2021
- ASKA Retracts Japan Application for Uterine Fibroid Med Ulipristal
September 28, 2021
- Astellas, Tohoku University Extend Collaboration for New Healthcare Solutions
September 27, 2021
- Startup Headed by Ex-Biogen Japan Chief Working to Develop New Alzheimer’s Drugs Using Photocatalysts
September 27, 2021
- Sawai Now Curbing Shipments for 432 Products
September 24, 2021
- Towa’s Shipment Restriction List Now Expands to 385 Products
September 24, 2021
- RaQualia Grants Global Rights for TRPM8 Blocker to HK Firm
September 24, 2021
- Ono, Honjo to Continue Settlement Discussions in Opdivo Royalty Feud
September 24, 2021
- Skyrizi’s New Dosage Forms Approved in Japan: AbbVie
September 24, 2021
- Shionogi to Begin PII/III Study for Oral COVID-19 Drug on Sept. 27: President
September 24, 2021
- Shionogi Gets New Oral COVID-19 Drug into Clinic in Less than 1 Year, Now Gearing Up for PII/III
September 24, 2021
- Hisamitsu Invests 200 Million Yen in Kyushu Univ. Regenerative Medicine Startup
September 24, 2021
- KM Biologics Moves Up COVID-19 Vaccine Target, Aims for Rollout in FY2022
September 22, 2021
- Takeda Grabs Japan Rights to Mirum’s Rare Liver Disease Drug
September 22, 2021
- Shionogi President Calls for Approval Systems to Respond to Emergency Situations
September 22, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…